Iproteos participates in a consortium awarded with a "RETOS" grant

You are here

The project named “Spark”, which is devoted to the development of a drug (IPR19) for the treatment of the cognitive impairment associated with schizophrenia, has obtained a “RETOS-Colaboración” grant from the Ministry of Economy and Competitiveness of Spain (RTC-2014-1645-1). Iproteos leads the consortium that is composed by the biopharmaceutical company Ascil-Biopharm, the University of the Basque Region (UPV/EHU), the Institute for Research in Biomedicine (IRB Barcelona) and the Centre for Genomic Regulation (CRG). The objective of “Spark” is the obtaining of an optimal formulation and the corresponding route of administration of IPR19. With a total of 500,000 € grant, the consortium will carry out the first preclinical stage of the novel drug candidate.